Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups-Reference-Cited by-同舟云学术

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Published:2016-03-24 Issue:12 Volume:127 Page:1551-1558
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Luskin Marlise R.¹,Lee Ju-Whei²,Fernandez Hugo F.³,Abdel-Wahab Omar⁴⁵,Bennett John M.⁶,Ketterling Rhett P.⁷,Lazarus Hillard M.⁸,Levine Ross L.⁴⁵,Litzow Mark R.⁹,Paietta Elisabeth M.¹⁰,Patel Jay P.⁴,Racevskis Janis¹⁰,Rowe Jacob M.¹¹,Tallman Martin S.⁵,Sun Zhuoxin²,Luger Selina M.¹

Affiliation:

1. Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;

2. Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Biostatistics Center, Dana-Farber Cancer Institute, Boston, MA;

3. Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL;

4. Human Oncology and Pathogenesis Program, and

5. Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY;

6. Department of Pathology, University of Rochester, Rochester, NY;

7. Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN;

8. Seidman Cancer Center, Case Western Reserve University, Cleveland, OH;

9. Department of Hematology, Mayo Clinic, Rochester, MN;

10. Department of Oncology, Montefiore Medical Center, Bronx, NY; and

11. Rambam Medical Center, Haifa, Israel

Abstract

Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/12/1551/1392308/1551.pdf

Reference31 articles.

1. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.;Yates;Cancer Chemother Rep,1973

2. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.;Yates;Blood,1982

3. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.;Holowiecki;J Clin Oncol,2012

4. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.;Hills;Lancet Oncol,2014

5. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.;Willemze;J Clin Oncol,2014

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CALCRL induces resistance to daunorubicin in acute myeloid leukemia cells through upregulation of XRCC5/TYK2/JAK1 pathway;Anti-Cancer Drugs;2023-11-10

2. The roles of TPL in hematological malignancies;Hematology;2023-07-04

3. Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia;Haematologica;2023-06-22

4. Paradigm Shift in the Management of Acute Myeloid Leukemia—Approved Options in 2023;Cancers;2023-05-31

5. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis;Cellular Signalling;2023-05